New services manage clinical or drug manufacturing data in the Verizon cloud or from data centers.
Verizon has added two new healthcare-industry solutions designed to help companies keep up with increasing regulatory requirements in the pharmaceutical sector. GxP (Good x Practices) Services will allow companies to manage sensitive clinical and drug-manufacturing data in the Verizon cloud or from select data centers. Verizon will also provide its complementary cloud and data-center service options in a new partnership with rfXcel, which provides a serialization solution that helps companies track and trace pharmaceuticals from manufacturing to distribution.
“Companies within the sector are struggling today to meet growing regulatory requirements,” said Rich Black, vice-president of Verizon’s healthcare practice. “We have found that our IT infrastructure, which leverages our cloud, security, and technical expertise, can enable them to address this burden.”
Verizon’s GxP services include colocation, managed hosting, and enterprise cloud solutions in three of the company’s global data centers, as well as professional services to size or scope the architecture and enable deployment. GxP services come with a baseline ISO 27001 certification. The services are managed under Verizon’s Quality Management Program to deliver qualified infrastructure with appropriate sign-offs on standard operating procedures and to ensure proper training, policies, and document/record control.
A cloud-based, track-and-trace software application is available to clients through rfXcel. This solution is a complete end-to-end service with compliance reporting that uses radio frequency identification (RFID) and a 2D barcode that can be integrated into current enterprise resource planning systems. The rfXcel solution offers serialization, traceability, alerts and notification, error detection and correction, and inventory management capabilities as well as an easy-to-use Web portal.
Source: Verizon Enterprise Solutions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.